National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

Medicine and Dentistry

• In Vitro 100%
• Pediatrics 66%
• Malignant Neoplasm 50%
• Cytotoxicity 50%
• Drug 50%
• Chemotherapeutic Agent 50%
• Pediatric Cancer 50%
• IC50 33%
• Ewing Family of Tumors 33%
• Cells 33%
• Clinical Trial 33%
• Chemotherapy 16%
• Xenograft 16%
• Lymphoma 16%
• Brain Tumor 16%
• Ganglioneuroblastoma 16%
• Cancer Cell Line 16%
• Cytotoxicity Assay 16%
• Vincristine 16%
• Childhood Cancer 16%
• Leukemia 16%
• Drug Screening 16%
• Mammalian Target of Rapamycin Inhibitor 16%
• Digital Imaging 16%
• Rhabdomyosarcoma 16%
• Etoposide 16%
• Rapamycin 16%
• Drug Activity 16%
• Melphalan 16%
• Fitting Curve 16%
• Cancer Model 16%
• Survival 16%
• Tenidap 16%
• Cell Line 16%